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Abstract For the first time, three different stefins, A, B and C, 
have been isolated from a single species. The complete amino acid 
sequence of bovine stefin A was determined. The inhibitor, with 
a calculated Mr of 11,123, consists of 98 amino acid residues. 
Although it exhibits considerable similarity to human and rat 
stefin A, some significant differences in inhibition kinetics were 
found. Bovine stefin A bound tightly and rapidly to cathepsin L 
(ka~ = 9.6.106 M-~-s -t, Kj = 29 pM). The binding to cathepsin 
H was also rapid (ka~ = 2.1 "106 M -I "s-J), but weaker (K i = 0.4 
nM) due to a higher dissociation rate constant. In contrast, the 
binding to cathepsin B was much slower (kas ~ = 1.4. l0  s M -I" s-~), 
hut still tight (Ks = 1.9 nM). 
Key words: Stefin; Cystatin; Cysteine proteinase; Cathepsin; 
Amino acid sequence 
tures of chicken cystatin [9] and stefin B in complex with papain 
[10], a novel enzyme-inhibitor binding mechanism was pro- 
posed. Three regions of the inhibitor were shown to interact 
with the enzyme: two hairpin loops and the N-terminal part 
[9,10], which appears to be more important in the cystatins 
[11-13]. 
In this paper we describe the purification and characteriza- 
tion of stefin A from bovine skin. The complete amino acid 
sequence of the inhibitor was determined and compared with 
other known sequences of inhibitors from the stefin family. 
Moreover, the kinetics of interaction of the isolated inhibitor 
with mammalian cysteine proteinases were characterized to 
clarify further the role of cystatins as potent physiological reg- 
ulators of cysteine proteinase activity. 
2. Materials and methods 
1. Introduction 
The lysosomal papain-like cysteine proteinases, which play 
an important role in intracellular protein degradation [1], are 
controlled by their endogenous protein inhibitors, the cystatins 
[2,3]. On the basis of sequence similarity, the cystatins can be 
divided into three evolutionarily related families of proteins: the 
stefins, the cystatins and the kininogens. The stefins (also called 
Family I cystatins) are small, acidic proteins, consisting of 
about 100 amino acid residues and lacking disulphide bonds. 
The cystatins (Family II cystatins) are somewhat larger pro- 
teins than the stefins, consisting of about 115 amino acid resi- 
dues and having two disulphide bridges. The best characterized 
representatives of the stefins are human stefins A and B [2,3]. 
Recently, we purified and characterized two members of the 
stefin family from bovine thymus, bovine stefins B and C [4,5]. 
Both the stefins and the cystatins are competitive, reversible 
inhibitors which form tight, equimolar complexes with their 
target proteinases [(~8]. On the basis of the X-ray crystal struc- 
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The amino acid sequence data reported in this paper will appear in the 
EMBL Database under the accession umber P80416 Stefin A from 
Bovin. 
2.1. Enzymes 
Papain (EC 3.4.22.2; 2x crystallized; Sigma), human cathepsin L (EC 
3.4.22.15) and bovine cathepsins B (EC 3.4.22.1) and H (EC 3.4.22.16) 
were purified [6,14-16] and active site titrated with Ep-475 (Peptide 
Research Institute) [5]. 
2.2. Purification of the inhibitors 
The inhibitors were purified from bovine skin by a method similar 
to that used for the purification of inhibitors from bovine thymus [5]. 
Following homogenization, alkaline treatment, affinity chromatogra- 
phy on Cm-papain-Sepharose and gel-filtration on a Sephadex G-50 
(Pharmacia-Biotech) olumn, the dialysed inhibitory sample was ap- 
plied to a DEAE-cellulose (Whatman) column (40 × 2 cm), equilibrated 
with 20 mM Tris buffer, pH 7.3. After thorough washing, the bound 
proteins were eluted with a linear gradient of NaCI (0-0.3 M) in the 
starting buffer. The inhibitory fractions were pooled and concentrated. 
SDS-PAGE and analytical isoelectric focusing were performed with 
the PhastSystem (Pharmacia-Biotech), following the instructions ofthe 
manufacturer. 
Protein concentrations were determined by absorption measure- 
ments at 280 nm with the use of absorption coefficients and molecular 
masses calculated from amino acid sequences with the Lasergene pro- 
gram (DNASTAR Inc.). 
The active concentration f the inhibitor was determined by fluores- 
cence titration with papain [6,7]. 
2.3. Sequence determination a d amino acid analysis 
10 nmol of inhibitor (bovine stefin A or bovine stefin C) were dis- 
solved in 70% formic acid. Crystalline CNBr (Pierce) was added in two 
portions in a 1 : 1 weight ratio immediately and after 24 h of incubation 
at room temperature in the dark. The reaction was terminated 12 h later 
by freeze-drying. 
Native stefin A (10 nmol) was digested with endoproteinase Lys-C 
(EC 3.4.21.50; Boehringer) at a 1:25 enzyme-to-substrate weight ratio 
for 24 h at room temperature in 0.3 M Tris buffer, pH 8.6, containing 
0.1 mM CaC12 and 5.0 M urea. The reaction was stopped by acidifica- 
tion to pH 3.0 with trifluoroacetic acid. 
Clostripain (EC 3.4.22.8; Sigma) digestion of stefin A was done in 
20 mM Tris buffer, pH 7.0, containing 10 mM CaC12, 0.005% (w/v) Brij 
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35 and 2.0 M urea at a proteinase-to-substrate weight ratio of 1:50. 
After 3 h at 40°C, the peptides were immediately separated by HPLC. 
Peptide mixtures were separated by HPLC (Milton Roy) on a re- 
verse-phase ChromSep C8 column (Chrompack), equilibrated with 
0.1% trifluoroacetic a id in water. The peptides were eluted with an 
acetonitrile gradient ((~70%) at a flow rate of 1 ml/min. The absorbance 
was continuously monitored at 215 nm. 
Amino acid analyses of hydrolyzed samples (24 h in 6.0 M HC1 at 
110°C) were performed on a 421 Amino Acid Analyzer (Applied Bio- 
systems) with pre-column phenylisothiocyanate derivatization. 
An Applied Biosystems 475A liquid-pulse sequencer, connected to
a 120A phenylthiohydantoin-amino acid analyzer f om the same man- 
ufacturer, was used for automated sequence analyses of the proteins. 
2.4. Kinetic measurements 
Papain was routinely assayed with Bz-DL-Arg-2-naphtylamide 
(Sigma) [17] as substrate in100 mM phosphate buffer, pH 6.0, contain- 
ing 1.5 mM EDTA and 2 mM dithiothreitol. The activity of the inhib- 
itors against papain throughout the course of the purification was 
determined under the same conditions. 
The kinetics of inhibition of cysteine proteinases were analysed at 
25°C as described for the thymus inhibitors [5]. All experiments were 
done under pseudo first-order conditions with at least enfold molar 
excess of the inhibitor. The following buffers were used: 100 mM phos- 
phate buffer, pH 6.0, for cathepsin B; 100 mM phosphate buffer, pH 
6.8, for cathepsin H; and 50 mM acetate buffer, pH 5.5, containing 100 
mM NaC1, for cathepsin L. All buffers also contained 1.5 mM EDTA 
and dimethylsulfoxide at aconcentration f 2.5% (v/v). Cathepsins B 
and L were assayed with 5/.tM Z-Phe-Arg-AMC (Peptide Research 
Institute) as substrate, whereas cathepsin H was assayed with l0 tiM 
Arg-AMC (Bachem). Substrate consumption was less than 3% in all 
experiments. 
3. Results 
3.1. Purification of inhibitors from skin 
A mixture of cysteine proteinase inhibitors from bovine skin 
was isolated by affinity chromatography on immobilized pa- 
pain and subsequently separated on an ion-exchange column. 
Seven papain-inhibiting peaks were obtained (not shown), of 
which four were identified as described below. The first peak, 
which did not bind to the column, was bovine cystatin C. Stefin 
B (peak 2) eluted at 0.06 M NaC1, stefin C (peak 5) at 0.18 M 
NaCI and stefin A (peak 6) at 0.20 M NaCI. The other peaks 
were not characterized. Additional attempts o separate the two 
isoforms of stefin A (see below) on a Mono Q column (Pharma- 
cia-Biotech) were unsuccessful; all the material bound to the 
column and was eluted as a symmetrical peak. From 1 kg of 
starting material we obtained 1.5 mg of stefin A. 
3.2. SDS-PA GE and analytical isoelectric focusing 
All the inhibitors migrated as single bands with Mr 12,000- 
14,000 in SDS-PAGE without reduction (not shown). In analyt- 
ical isoelectric focusing, cystatin C was shown to be the only 
basic inhibitor with a pI value of 8.2. Stefins B and C showed 
single bands with pI values of 5.6 and 4.8, respectively, whereas 
stefin A appeared in two isoforms with pI values 4.7 and 4.95, 
similar to the human and rat variants [2]. All other inhibitory 
proteins were acidic with pI values ranging from 4.5 to 6.5 
(Fig. 1). 
3.3. N-Terminal sequencing and amino acid analyses 
The N-terminal sequence of the first inhibitory peak from 
DEAE-cellulose, LGGLMEADV, together with amino acid 
analysis, identified the protein as a truncated form of bovine 
cystatin C [18]. The protein in the second peak was N-termi- 
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Fig. 1. Isoelectric focusing of the purified inhibitors after ion-exchange 
chromatography. Lane 1, peak 1 (cystatin C); lane 2, peak 2 (stefin B); 
lane 3, peak 3; lane 4, standards; lane 5, peak 4; lane 6, peak 5 (stefin C); 
lane 7, peak 6 (stefin A); lane 8, peak 7. 
nally blocked; however, amino acid analysis howed that it was 
identical to bovine stefin B from thymus [4]. The N-terminus 
of the fifth inhibitory peak was also blocked, but sequence 
analysis of the second CNBr fragment of this protein identified 
it as fulMength stefin C [5]. The sixth inhibitory peak was 
identified as bovine stefin A by total sequence determination, 
as described below. 
3.4. Sequence determination of stefin A 
N-Terminal sequence analysis of native stefin A gave a single 
sequence up to residue 32 (uncleaved molecule in Fig. 2). A very 
high initial yield of the run (>95%) indicated that the cz-amino 
group of the inhibitor was not blocked. The sequence revealed 
a Met residue at position 22, and therefore the first set of 
peptides was prepared by CNBr cleavage (CN peptides in Fig. 
2). The resulting two peptides were sequenced, and the CN-1 
peptide was found to correspond to the N-terminal part of the 
inhibitor, whereas the CN-2 peptide corresponded to the stefin 
A sequence from Val-23 onwards. 
Two other sets of peptides were prepared from stefin A by 
endoproteinase Lys-C (K-peptides in Fig. 2) and clostripain 
(R-peptides in Fig. 2) digestions. The sequence of the C-termi- 
nal part of the inhibitor was established from the K-7 (residues 
72-89) and K-8 (residues 90-98) peptides. The K-8 peptide 
ended with Phe, which is not a cleavage site of the highly 
specific Lys-C endoproteinase, indicating that the C-terminal 
residue is Phe, as in all other inhibitors of the stefin family (Fig. 
2). The sequence of the R-2 peptide (residues 64-93) provided 
the overlap between the K-6, K-7 and K-8 peptides. 
3.5. Amino acid sequence comparison 
Alignment of the amino acid sequence ofbovine stefin A with 
those of other stefins (Fig. 3) showed that the sequence identity 
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Fig. 2. Complete primary structure of bovine stefin A. CN, peptides obtained by CNBr cleavage; K, peptides from endoproteinase Lys-C digestion; 
R, peptides from clostripain digestion. 
with porcine leukocyte cysteine proteinase inhibitor and human 
stefin A is 72%, with rat stefin A 55%, with bovine stefin B 49%, 
with human stefin B 48% and with rat stefin B and bovine stefin 
C 47%. 
3.6. Inhibition kinetics 
The interaction kinetics of bovine stefin A with the cysteine 
proteinases cathepsins B, H and L were characterized under 
pseudo first-order conditions by continuous fluorimetric as- 
says. All progress curves showed an exponential pproach to 
a final linear ate and were analyzed by the least-squares fitting 
of the appropriate integrated rate equation [19] to the experi- 
mental data. The linearity of product formation in separate 
experiments without inhibitors verified that the enzymes were 
stable during the experiments. A linear dependence of the ob- 
served pseudo first-order rate constant on inhibitor concentra- 
tion was observed for all enzyme-inhibitor pairs investigated 
(Fig. 4), consistent with a simple, competitive inhibition mech- 
anism [8,19]. Apparent second-order association rate constants, 
kass, were obtained from the slopes of these plots. No correction 
for substrate concentration was necessary for cathepsins B and 
H, as the substrate concentrations were appreciably ower than 
the Km values for the enzymes, i.e. 150/.tM for cathepsin B [20] 
and 115 + 20 ~tM, determined in this work, for cathepsin H. 
However, the kas values for cathepsin L were corrected with the 
use of a Km of 2/IM [21]. Most dissociation rate constants, kdiss, 
could not be obtained from these measurements, a  the inter- 
cept on the ordinate was indistinguishable from zero. However, 
the kdiss value for the interaction with cathepsin H, estimated 
from this intercept, was in good agreement with the value cal- 
culated as described below. 
K~ values were calculated by linear regression analysis of the 
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Fig. 3. Alignment of the amino acid sequence ofbovine stefin A with those of other stefins. BSTA, bovine stefin A; HSTA, human stefin A; PLCPI, 
porcine leukocyte CPI [28]; RCA, rat cystatin ct; HSTB, human stefin B; RCB, rat cystatin fl; BSTB, bovine stefin B [4]; BSTC, bovine stefin C [5]. 
Residues identical to those in bovine stefin A are marked with a flled square; the numbering isthat of bovine stefin A. Other references are listed 
in Turk and Bode [3]. 
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Fig. 4. Dependence of the observed pseudo first-order ate constant 
(kob~) on the inhibitor concentration forthe interaction between bovine 
stefin A and cathepsins B, H and L. (e) Cathepsin B; (..) cathepsin H; 
(o) cathepsin L. Experimental conditions are described in section 2. The 
solid lines were generated using the best estimates for apparent k,,, and 
ka,s, obtained by linear regression analysis according to Morrison [19]. 
initial (vz) and steady-state (vs) rates of substrate hydrolysis 
obtained at different inhibitor concentrations according to 
Morrison [19]. All plots of (v f lv  S - 1) vs. [Io] gave straight lines. 
Again, corrections for substrate competition were necessary 
only for cathepsin L. The kd~ss values were calculated from K~ 
and kas values (kj~s = K i • kass). All kinetic and equilibrium con- 
stants are given in Table 1. 
4. Discussion 
Several ow-Mr inhibitors of cysteine proteinases, including 
cystatin C, stefin A, stefin B and stefin C, were isolated from 
bovine skin. This is the first time that three different inhibitors 
of the stefin family have been isolated from a single species. 
Stefin A was found to be the most abundant inhibitor, in agree- 
ment with previous tudies with rat and human stefin A, show- 
ing a high level of this inhibitor in skin [2]. 
The sequence of bovine stefin A showed considerable simi- 
larity with those of other stefins, especially human stefin A and 
porcine leukocyte CPI. The sequence identity with human ste- 
fin A is high in the N-terminal part (86% in the first 35 residues) 
and in the C-terminal part (88% in the last 17 residues), whereas 
it is lower in the middle part of the molecule. The central 
Table 1 
Kinetic data for the interaction between cathepsins B, H and L and 
bovine stefin A 
Enzyme 10 -5 x k,~, Ki 104 x kdiss 
(M -l' s -l) (nM) (s -l) 
Cathepsin B 1.4 _+ 0.15 (7) 1.79 + 0.10 (6) 2.5 
Cathepsin H 21.0 _+ 1.0 (8) 0.44 + 0.03 (7) 9.2 
Cathepsin L 96.5 _+ 5.3 (7) 0.029 + 0.003 (7) 2.8 
The experimental conditions are described in section 2. The best esti- 
mates for the association rate constants (ka~s) and equilibrium constants 
(K,), together with their standard errors, were calculated as described 
in section 3. The dissociation rate constants (kaJ were calculated 
from K, and kas~ values. The number of measurements is given in 
parentheses. 
QVVAG region is conserved in bovine stefin A, as in other 
stefins, except bovine stefin B, in which the first Val is replaced 
by Leu [4]. 
Kinetic and equilibrium studies revealed that bovine stefin 
A binds rapidly and tightly to cathepsin L, with a K~ value 
substantially ower than that reported earlier for human stefin 
A [22]. The rate and equilibrium constants for the other two 
enzymes are in good agreement with previously reported values 
for the human inibitor [22,23]. However, the inhibitory proper- 
ties of bovine stefin A differ from those of bovine stefins B and 
C, especially with regard to the tight inhibition of cathepsin B
[51. 
The kinetic data indicate that the mechanism of inhibition of 
cysteine proteinases by stefin A is different for different pro- 
teinases. The mechanism of cathepsin L inhibition resembles 
most closely that of papain, the only enzyme for which the 
mechanism is known [9,10]. The complex with cathepsin H was 
formed rapidly as well, but was more unstable, partly due to 
a higher dissociation rate constant. An octapeptide of the pro- 
region remains bound to mature cathepsin H via a disulphide 
bond in the vicinity of the active site at the $2 subsite [24]. This 
octapeptide may substantially influence or even prevent bind- 
ing of N-terminal residues of inhibitors to cathepsin H, consis- 
tent with the high dissociation rate constant. The rate of asso- 
ciation of stefin A with cathepsin B was appreciably lower than 
that with the other enzymes. The crystal structure of human 
cathepsin B shows an additional loop, not present in papain, 
of about 20 amino acid residues, which partially occludes the 
active site. This loop was proposed to interfere with inhibitor 
binding [25], a suggestion supported by observations that the 
association rate constants for the interactions of inhibitors with 
cathepsin B are markedly lower than those for the binding to 
other enzymes [11,12,23]. 
A proteinase inhibitor can be of physiological importance if
inhibition is achieved at physiological concentrations of the 
inhibitor in a sufficiently short time with negligible dissociation 
of the complex [26]. Stefin A entirely fulfils these conditions for 
all three enzymes investigated and may thus be involved in the 
control of endogenous cysteine proteinases. It may also play a 
protective role against invasive organisms that use cysteine 
proteinases for penetration [27]. 
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